Solid dosage forms* preformulation

Nyqvist H, Wadsten T. Preformulation of solid dosage forms light stability testing of polymorphs as a part of a preformulation process. Acta Pharm Technol 1986 32 130-132. 

Preformulation in Solid Dosage Form Development, edited by Moji Christianah Adeyeye and Harry G. Brittain... 

Davies P. 2004. Oral solid dosage form. In Gibson M, editor. Pharmaceutical preformulation and formulation. Interpharm/CRC New York 379-456. 

ROLE OF PREFORMULATION IN DEVELOPMENT OF SOLID DOSAGE FORMS... 

Omanthanu P. Perumal, South Dakota State University, Brookings, South Dakota, Role of Preformulation in Development of Solid Dosage Forms... 

Heidemann, D.R. Jarosz, P.J. Preformulation studies involving moisture uptake in solid dosage forms. Pharm. Res. 1991, 8, 292-297. 

Early on in product development, the potential for the successful development of a solid oral dosage form is assessed, based on the physicochemical properties of the API (1). Prior to solid dosage form development, it is necessary to anticipate the physicochemical properties that can have a major influence on product manufacture and performance. The early development (preformulation and early formulation development) studies should focus on these properties so as to avoid problems at later stages of development. While the molecular properties dictate the intrinsic solubility and the chemical stability of the compound, by controlling the physical form of the compound and by modifying physical properties (e.g., particle size), the dissolution rate can be enhanced with the potential for improving bioavailability. This chapter will focus on physical properties including particle characteristics, and most importantly, the physical form (i.e., solid state) of the API. 

---